Ironwood is counting on a new rare-disease drug and steady demand for its leading gut treatment to keep growth going as digestive health problems become more common with age. The catch is that the business leans heavily on one product, while drug-pricing pressure and tough insurance negotiations could crimp what those launches deliver.Read more
Ironwood is betting its future on a new gut therapy while its current flagship medicine keeps the lights on, and a recent reshuffle is meant to make the business leaner and more profitable. The catch is that drug pricing pressure and a heavy debt load could squeeze sales and limit how much upside investors actually see.Read more
Ironwood’s growth story hinges on two drugs: one that already brings in most of the money and another that still needs a green light to launch. But changes in how medicines get paid for, plus delays and tougher competition, could keep results from improving as much as investors hope.Read more
No trending discussion available.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
